AU2014225604B2 - Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use - Google Patents
Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use Download PDFInfo
- Publication number
- AU2014225604B2 AU2014225604B2 AU2014225604A AU2014225604A AU2014225604B2 AU 2014225604 B2 AU2014225604 B2 AU 2014225604B2 AU 2014225604 A AU2014225604 A AU 2014225604A AU 2014225604 A AU2014225604 A AU 2014225604A AU 2014225604 B2 AU2014225604 B2 AU 2014225604B2
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- independently
- pharmaceutically acceptable
- acceptable salt
- oxa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CCC(C)C1(*)*=C(N)OC2[C@]1C(*)(CCC*)C2*=I Chemical compound CCC(C)C1(*)*=C(N)OC2[C@]1C(*)(CCC*)C2*=I 0.000 description 11
- SQEJJKZVOKBGOC-UHFFFAOYSA-N FCC1=NOC2C1C2 Chemical compound FCC1=NOC2C1C2 SQEJJKZVOKBGOC-UHFFFAOYSA-N 0.000 description 2
- ZSFXFSXZNGXLOL-ORIITIJXSA-N CC1(C)OB(c(cc2[C@@]3(C(F)F)N=C(N)O[C@H]4C3C4)ccc2F)OC1(C)C Chemical compound CC1(C)OB(c(cc2[C@@]3(C(F)F)N=C(N)O[C@H]4C3C4)ccc2F)OC1(C)C ZSFXFSXZNGXLOL-ORIITIJXSA-N 0.000 description 1
- OZKVFTVZLFSJQX-UHFFFAOYSA-N COc1cnc(C(O)=O)c(OC)n1 Chemical compound COc1cnc(C(O)=O)c(OC)n1 OZKVFTVZLFSJQX-UHFFFAOYSA-N 0.000 description 1
- JMWBULAEPUJAET-UHFFFAOYSA-N C[BrH]c(cc1C2=NOC(CCCl)C2)ccc1F Chemical compound C[BrH]c(cc1C2=NOC(CCCl)C2)ccc1F JMWBULAEPUJAET-UHFFFAOYSA-N 0.000 description 1
- AUTSGNLBLKCPOP-MYLCTYFISA-N C[C@@H]([C@H]1[C@](C(F)F)(c(cc(cc2C)Br)c2F)N)[C@@H]1O Chemical compound C[C@@H]([C@H]1[C@](C(F)F)(c(cc(cc2C)Br)c2F)N)[C@@H]1O AUTSGNLBLKCPOP-MYLCTYFISA-N 0.000 description 1
- LMVFWAIEZLZSIC-RFBVYIQQSA-N C[C@@]1(c2cc(Br)ccc2F)NOC2C1C2 Chemical compound C[C@@]1(c2cc(Br)ccc2F)NOC2C1C2 LMVFWAIEZLZSIC-RFBVYIQQSA-N 0.000 description 1
- FTYZZXLNPNJMRB-PRHODGIISA-N C[C@H](C[C@@](CF)(c(cc(C)cc1Cl)c1F)N)O Chemical compound C[C@H](C[C@@](CF)(c(cc(C)cc1Cl)c1F)N)O FTYZZXLNPNJMRB-PRHODGIISA-N 0.000 description 1
- KESDRZCXXUFEEI-GUJYYOPSSA-N C[C@]1(c2cc(Br)ccc2Cl)NO[C@H]2C1C2 Chemical compound C[C@]1(c2cc(Br)ccc2Cl)NO[C@H]2C1C2 KESDRZCXXUFEEI-GUJYYOPSSA-N 0.000 description 1
- LFUCFNQACDDZJO-FMDDCXKFSA-N Cc1cc(Br)cc([C@@]2(C(F)F)NOC3C2C3)c1F Chemical compound Cc1cc(Br)cc([C@@]2(C(F)F)NOC3C2C3)c1F LFUCFNQACDDZJO-FMDDCXKFSA-N 0.000 description 1
- LYPIZRPLQAZORW-BWEXCOOYSA-N Cc1cc(Br)cc([C@](C(F)F)(C(C2)[C@@H]2O)N)c1F Chemical compound Cc1cc(Br)cc([C@](C(F)F)(C(C2)[C@@H]2O)N)c1F LYPIZRPLQAZORW-BWEXCOOYSA-N 0.000 description 1
- UQMVAYYSEZULCD-HIYWGVSTSA-N Cc1cc([BrH]C)cc([C@](C(F)F)(C(C2)[C@@H]2O)N)c1F Chemical compound Cc1cc([BrH]C)cc([C@](C(F)F)(C(C2)[C@@H]2O)N)c1F UQMVAYYSEZULCD-HIYWGVSTSA-N 0.000 description 1
- LAZRDNVJULFFKB-UHFFFAOYSA-N FC(C1=NOC2C1C2)F Chemical compound FC(C1=NOC2C1C2)F LAZRDNVJULFFKB-UHFFFAOYSA-N 0.000 description 1
- GEMFBSOAWNIIEF-IMDWOCAISA-N FC[C@]1(c(cccc2Cl)c2F)NOC2[C@@H]1C2 Chemical compound FC[C@]1(c(cccc2Cl)c2F)NOC2[C@@H]1C2 GEMFBSOAWNIIEF-IMDWOCAISA-N 0.000 description 1
- NUWGEJRCZCAART-UHFFFAOYSA-N Fc(c(C1=NOC2C1C2)c1)ccc1Br Chemical compound Fc(c(C1=NOC2C1C2)c1)ccc1Br NUWGEJRCZCAART-UHFFFAOYSA-N 0.000 description 1
- GYCNHFWRPJXTSB-UHFFFAOYSA-N N#Cc1cc(Br)ccc1F Chemical compound N#Cc1cc(Br)ccc1F GYCNHFWRPJXTSB-UHFFFAOYSA-N 0.000 description 1
- ZMXSZCPKYCETFL-YWEYNIOJSA-N N/C(/c1cc(Br)ccc1F)=C\O Chemical compound N/C(/c1cc(Br)ccc1F)=C\O ZMXSZCPKYCETFL-YWEYNIOJSA-N 0.000 description 1
- SUXKEJZFELZDQS-UHFFFAOYSA-N NC(CF)(C(C1)C1O)c1cc(Br)ccc1Cl Chemical compound NC(CF)(C(C1)C1O)c1cc(Br)ccc1Cl SUXKEJZFELZDQS-UHFFFAOYSA-N 0.000 description 1
- MOYMIMBIBLCWNB-GARJUAAWSA-N NC(OC1[C@@H]2C1)=N[C@]2(C(F)F)c1cc(-c2nnc(-c(cc3)ccc3F)[nH]2)ccc1F Chemical compound NC(OC1[C@@H]2C1)=N[C@]2(C(F)F)c1cc(-c2nnc(-c(cc3)ccc3F)[nH]2)ccc1F MOYMIMBIBLCWNB-GARJUAAWSA-N 0.000 description 1
- MBQOMBDMUYOZER-JJMHPEDZSA-N NC(O[C@@H]1C=C[C@@H]11)=NC1(CF)c(cccc1Cl)c1F Chemical compound NC(O[C@@H]1C=C[C@@H]11)=NC1(CF)c(cccc1Cl)c1F MBQOMBDMUYOZER-JJMHPEDZSA-N 0.000 description 1
- SJJKMSGAVIZURQ-XTOKZYMASA-N NC(O[C@H]1C2C1)=N[C@]2(C(F)F)c1cc(Br)ccc1F Chemical compound NC(O[C@H]1C2C1)=N[C@]2(C(F)F)c1cc(Br)ccc1F SJJKMSGAVIZURQ-XTOKZYMASA-N 0.000 description 1
- SUUKHIFMZQJKSQ-JCKWVBRZSA-N NC(O[C@H]1[C@@H]2C1)=N[C@]2(CF)c1cc(NC(c(nc2)ccc2Cl)=O)ccc1 Chemical compound NC(O[C@H]1[C@@H]2C1)=N[C@]2(CF)c1cc(NC(c(nc2)ccc2Cl)=O)ccc1 SUUKHIFMZQJKSQ-JCKWVBRZSA-N 0.000 description 1
- CIOMNNOVGZBNAK-XFFZJAGNSA-N O/N=C(/c1cc(Br)ccc1F)\Cl Chemical compound O/N=C(/c1cc(Br)ccc1F)\Cl CIOMNNOVGZBNAK-XFFZJAGNSA-N 0.000 description 1
- FUTIPQFMRMIGDD-FSGMKPHLSA-N O=C(c1ccccc1)NC(O[C@H]1[C@@H]2C1)=NC2(CF)c1cc(Br)ccc1Cl Chemical compound O=C(c1ccccc1)NC(O[C@H]1[C@@H]2C1)=NC2(CF)c1cc(Br)ccc1Cl FUTIPQFMRMIGDD-FSGMKPHLSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361775380P | 2013-03-08 | 2013-03-08 | |
| US61/775,380 | 2013-03-08 | ||
| US201461939580P | 2014-02-13 | 2014-02-13 | |
| US61/939,580 | 2014-02-13 | ||
| PCT/US2014/021412 WO2014138484A1 (en) | 2013-03-08 | 2014-03-06 | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2014225604A1 AU2014225604A1 (en) | 2015-09-10 |
| AU2014225604B2 true AU2014225604B2 (en) | 2018-05-17 |
Family
ID=50478936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014225604A Active AU2014225604B2 (en) | 2013-03-08 | 2014-03-06 | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US9085576B2 (enExample) |
| EP (1) | EP2964644B1 (enExample) |
| JP (1) | JP6374889B2 (enExample) |
| KR (1) | KR20150124985A (enExample) |
| CN (1) | CN105164121A (enExample) |
| AP (1) | AP2015008716A0 (enExample) |
| AU (1) | AU2014225604B2 (enExample) |
| BR (1) | BR112015021336A2 (enExample) |
| CA (1) | CA2903215C (enExample) |
| CL (1) | CL2015002516A1 (enExample) |
| CR (1) | CR20150519A (enExample) |
| EA (1) | EA201591614A1 (enExample) |
| HK (1) | HK1217486A1 (enExample) |
| IL (1) | IL240829A0 (enExample) |
| MX (1) | MX374512B (enExample) |
| PE (1) | PE20151794A1 (enExample) |
| PH (1) | PH12015502001A1 (enExample) |
| SG (1) | SG11201507196WA (enExample) |
| TN (1) | TN2015000382A1 (enExample) |
| TW (1) | TW201446760A (enExample) |
| UY (1) | UY35377A (enExample) |
| WO (1) | WO2014138484A1 (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8637504B2 (en) | 2008-06-13 | 2014-01-28 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity |
| RU2012129168A (ru) | 2009-12-11 | 2014-01-20 | Сионоги Энд Ко. Лтд. | Производные оксазина |
| JP2016501827A (ja) | 2012-10-24 | 2016-01-21 | 塩野義製薬株式会社 | Ｂａｃｅ１阻害作用を有するジヒドロオキサジンまたはオキサゼピン誘導体 |
| AU2014223334C1 (en) | 2013-03-01 | 2018-10-18 | Amgen Inc. | Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| EP2964644B1 (en) | 2013-03-08 | 2018-12-26 | Amgen, Inc. | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| BR112015022762B1 (pt) | 2013-03-13 | 2022-08-16 | Takeda Pharmaceutical Company Limited | Composto de éster do ácido guanidinobenzóico, composição farmacêutica, e, uso do composto |
| US9428470B2 (en) | 2014-02-13 | 2016-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US9346776B2 (en) | 2014-02-13 | 2016-05-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| MX381482B (es) | 2014-08-08 | 2025-03-12 | Amgen Inc | Compuestos de tiazin-2-amina fusionados con ciclopropilo como inhibidores de beta-secretasa y metodos de uso. |
| US9868738B2 (en) * | 2014-09-19 | 2018-01-16 | Merck Sharp & Dohme Corp. | Diazine-fused amidines as BACE inhibitors, compositions, and their use |
| WO2016118404A1 (en) * | 2015-01-20 | 2016-07-28 | Merck Sharp & Dohme Corp. | Iminothiadiazine dioxides bearing an amine-linked substituent as bace inhibitors, compositions, and their use |
| CN107709295B (zh) | 2015-05-07 | 2021-05-04 | 百时美施贵宝公司 | 作为RORγ调节剂的三环砜类 |
| AR105607A1 (es) * | 2015-08-07 | 2017-10-18 | Bayer Cropscience Ag | Derivados heterocíclicos condensados sustituidos por 2-(het)arilo como pesticidas |
| US20170107216A1 (en) | 2015-10-19 | 2017-04-20 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| EP3165093A1 (en) | 2015-11-05 | 2017-05-10 | Basf Se | Substituted oxadiazoles for combating phytopathogenic fungi |
| MD3377488T2 (ro) | 2015-11-19 | 2023-02-28 | Incyte Corp | Compuși heterociclici ca imunomodulatori |
| ES2916874T3 (es) | 2015-12-17 | 2022-07-06 | Incyte Corp | Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1 |
| CA3009474A1 (en) * | 2015-12-22 | 2017-06-29 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| ES2906460T3 (es) | 2016-05-06 | 2022-04-18 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| EP3464279B1 (en) | 2016-05-26 | 2021-11-24 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| SG11201811414TA (en) | 2016-06-20 | 2019-01-30 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| MA45669A (fr) | 2016-07-14 | 2019-05-22 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| US20180057486A1 (en) | 2016-08-29 | 2018-03-01 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| CN106432071B (zh) * | 2016-09-05 | 2019-04-02 | 河北正朗制药有限公司 | 5-氰基-4-甲氧基-2-吡啶甲酸的盐酸盐的制备及其应用 |
| US10968177B2 (en) | 2016-10-10 | 2021-04-06 | Bristol-Myers Squibb Company | Tricyclic sulfones as RORγ modulators |
| AU2017376445B2 (en) | 2016-12-15 | 2021-09-30 | Amgen Inc. | Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use |
| MX386618B (es) | 2016-12-15 | 2025-03-19 | Amgen Inc | Derivados de tiazina condensados con ciclopropilo como inhibidores de beta-secretasa y métodos de uso. |
| MX388697B (es) | 2016-12-15 | 2025-03-20 | Amgen Inc | Derivados de tiazina como inhibidores de beta-secretasa y metodos de uso. |
| MX387729B (es) | 2016-12-15 | 2025-03-18 | Amgen Inc | Derivados de dióxido de 1,4-tiazina y dióxido 1,2,4-tiadiazina como inhibidores de beta-secretasa y métodos de uso. |
| AU2017376441B2 (en) * | 2016-12-15 | 2021-10-14 | Amgen Inc. | Oxazine derivatives as beta-secretase inhibitors and methods of use |
| US10308644B2 (en) | 2016-12-22 | 2019-06-04 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2018119236A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
| WO2018119221A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| WO2018119286A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| EP4223369A1 (en) | 2016-12-22 | 2023-08-09 | Incyte Corporation | Immunomodulator compounds and methods of use |
| SMT202300065T1 (it) | 2018-03-30 | 2023-05-12 | Incyte Corp | Composti eterociclici come immunomodulatori |
| BR112020021728A2 (pt) | 2018-04-27 | 2021-01-26 | Shionogi & Co., Ltd. | derivados de tetra-hidropiranooxazina tendo atividade inibitória de bace1 seletiva |
| CN112752756B (zh) | 2018-05-11 | 2024-06-25 | 因赛特公司 | 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物 |
| CN110759860B (zh) * | 2018-07-27 | 2022-10-14 | 江苏瑞科医药科技有限公司 | 一种3-甲酸甲酯-4-甲氧基-5-氰基吡啶的制备方法 |
| CN109430267A (zh) * | 2018-10-24 | 2019-03-08 | 南京华安药业有限公司 | 一种肟草酮水悬浮剂 |
| CN110183392B (zh) * | 2019-06-14 | 2023-03-28 | 河北医科大学 | 一种3-取代苯基-4，5-二氢异噁唑衍生物的制备方法及其用途和中间体 |
| TW202115059A (zh) | 2019-08-09 | 2021-04-16 | 美商英塞特公司 | Ｐｄ—１／ｐｄ—ｌ１抑制劑之鹽 |
| JP7559059B2 (ja) | 2019-09-30 | 2024-10-01 | インサイト・コーポレイション | 免疫調節剤としてのピリド［３，２－ｄ］ピリミジン化合物 |
| EP4058461A1 (en) | 2019-11-11 | 2022-09-21 | Incyte Corporation | Salts and crystalline forms of a pd-1/pd-l1 inhibitor |
| CN110885329B (zh) | 2019-12-16 | 2020-12-15 | 诚达药业股份有限公司 | 一种1,7-萘啶衍生物的合成方法 |
| CN113087669B (zh) * | 2019-12-23 | 2023-11-17 | 南京药石科技股份有限公司 | 一种4-氰基-5-溴嘧啶的制备方法 |
| JP2023523779A (ja) | 2020-05-05 | 2023-06-07 | ビーエーエスエフ ソシエタス・ヨーロピア | 縮合イソオキサゾリン誘導体及び除草剤としてのそれらの使用 |
| US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
| IL302590A (en) | 2020-11-06 | 2023-07-01 | Incyte Corp | Process for preparing PD-1/PD-L1 inhibitor and salts and crystalline forms thereof |
| US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
| TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Ａｌｋ﹘５抑制劑和彼之用途 |
| PE20260291A1 (es) | 2023-04-05 | 2026-02-10 | Moma Therapeutics Inc | Derivados biciclicos semisaturados y usos relacionados |
| CN118852012A (zh) * | 2024-09-26 | 2024-10-29 | 山东国邦药业有限公司 | 一种高收率的二氟吡唑酸的合成方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2511268A1 (en) * | 2009-12-11 | 2012-10-17 | Shionogi & Co., Ltd. | Oxazine derivative |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5441870A (en) | 1992-04-15 | 1995-08-15 | Athena Neurosciences, Inc. | Methods for monitoring cellular processing of β-amyloid precursor protein |
| SI9300303A (en) | 1993-06-08 | 1994-12-31 | Krka Tovarna Zdravil | Process for isolation of hypolipemic effective substance |
| JPH11507538A (ja) | 1995-06-07 | 1999-07-06 | アテナ ニューロサイエンシズ インコーポレイティド | β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ |
| ES2318902T3 (es) | 1998-09-24 | 2009-05-01 | PHARMACIA & UPJOHN COMPANY LLC | Secretasa en la enfermedad del alzheimer. |
| US20040234976A1 (en) | 1998-09-24 | 2004-11-25 | Gurney Mark E. | Alzheimer's disease secretase, app substrates therefor, and uses therefor |
| CA2548388A1 (en) | 2003-12-15 | 2005-06-30 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| ES2537898T3 (es) | 2005-10-25 | 2015-06-15 | Shionogi & Co., Ltd. | Derivados de aminotiazolidina y aminotetrahidrotiazepina como inhibidores de BACE 1 |
| EP2096111A1 (en) | 2006-11-20 | 2009-09-02 | Japan Tobacco Inc. | Pyrazoles and use thereof as drugs |
| AU2008245082B8 (en) | 2007-04-24 | 2012-09-13 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives substituted with a cyclic group |
| EP2151435A4 (en) | 2007-04-24 | 2011-09-14 | Shionogi & Co | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| EA015952B1 (ru) | 2007-05-03 | 2011-12-30 | Пфайзер Лимитед | 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов |
| BRPI0906962B8 (pt) | 2008-01-18 | 2021-05-25 | Eisai R&D Man Co Ltd | composto de aminodiidrotiazina fundido |
| TWI431004B (zh) | 2008-05-02 | 2014-03-21 | Lilly Co Eli | Ｂａｃｅ抑制劑 |
| US8637504B2 (en) | 2008-06-13 | 2014-01-28 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity |
| AU2009277485B2 (en) | 2008-07-28 | 2013-05-02 | Eisai R&D Management Co., Ltd. | Spiroaminodihydrothiazine derivatives |
| WO2010013302A1 (ja) | 2008-07-28 | 2010-02-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | スピロアミノジヒドロチアジン誘導体 |
| US8461160B2 (en) | 2009-05-08 | 2013-06-11 | Hoffmann-La Roche, Inc. | Dihydropyrimidinones |
| AR077277A1 (es) | 2009-07-09 | 2011-08-17 | Lilly Co Eli | Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer |
| GB0912778D0 (en) | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydro-oxazine derivatives |
| US8188079B2 (en) | 2009-08-19 | 2012-05-29 | Hoffman-La Roche Inc. | 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines |
| US20110065695A1 (en) | 2009-09-11 | 2011-03-17 | Jeremy Beauchamp | Use of aminodihydrothiazines for the treatment or prevention of diabetes |
| UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| CN102686584A (zh) | 2009-11-13 | 2012-09-19 | 盐野义制药株式会社 | 具有氨基连接基的氨基噻嗪或氨基噁嗪衍生物 |
| WO2011071057A1 (ja) | 2009-12-09 | 2011-06-16 | 塩野義製薬株式会社 | 含硫黄複素環誘導体を含有するアルツハイマー症の治療用または予防用医薬組成物 |
| US20120245154A1 (en) | 2009-12-09 | 2012-09-27 | Shionogi & Co., Ltd. | Substituted aminothiazine derivative |
| US7964594B1 (en) | 2009-12-10 | 2011-06-21 | Hoffmann-La Roche Inc. | Amino oxazine derivatives |
| UA103272C2 (uk) | 2009-12-11 | 2013-09-25 | Ф. Хоффманн-Ля Рош Аг | 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2 |
| US20120245155A1 (en) | 2009-12-11 | 2012-09-27 | Shionogi & Co., Ltd. | Fused heterocyclic compound having amino group |
| US8673894B2 (en) * | 2010-05-07 | 2014-03-18 | Hoffmann-La Roche Inc. | 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds |
| CN103429589A (zh) | 2011-01-12 | 2013-12-04 | 诺瓦提斯公司 | 噁嗪衍生物及其在治疗神经障碍中的用途 |
| EA201391033A1 (ru) | 2011-01-13 | 2014-01-30 | Новартис Аг | Ингибиторы bace-2 для лечения метаболических расстройств |
| US8404680B2 (en) | 2011-02-08 | 2013-03-26 | Hoffmann-La Roche Inc. | N-[3-(5-amino-3,3a,7,7a-tetrahydro-1H-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as BACE1 and/or BACE2 inhibitors |
| WO2012138734A1 (en) | 2011-04-07 | 2012-10-11 | Merck Sharp & Dohme Corp. | C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| US8754075B2 (en) | 2011-04-11 | 2014-06-17 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE1 and/or BACE2 inhibitors |
| BR112013026341A2 (pt) | 2011-04-13 | 2019-09-24 | Merck Sharp & Dohe Corp. | composto, composição farmacêutica, e, método para tratar, prevenir e/ou atrasar o início de uma doença ou patologia |
| WO2012147762A1 (ja) | 2011-04-26 | 2012-11-01 | 塩野義製薬株式会社 | ピリジン誘導体およびそれを含有するｂａｃｅ１阻害剤 |
| WO2012147763A1 (ja) | 2011-04-26 | 2012-11-01 | 塩野義製薬株式会社 | オキサジン誘導体およびそれを含有するｂａｃｅ１阻害剤 |
| US8785436B2 (en) | 2011-05-16 | 2014-07-22 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE 1 and/or BACE2 inhibitors |
| US8604024B2 (en) | 2011-05-24 | 2013-12-10 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
| TW201302763A (zh) | 2011-05-24 | 2013-01-16 | 必治妥美雅史谷比公司 | 用於減少β－類澱粉產生之化合物 |
| US9079919B2 (en) | 2011-05-27 | 2015-07-14 | Hoffmann-La Roche Inc. | Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors |
| JP2012250933A (ja) | 2011-06-03 | 2012-12-20 | Shionogi & Co Ltd | オキサジン誘導体を含有するアルツハイマー症治療用または予防用医薬組成物 |
| AR086653A1 (es) | 2011-06-03 | 2014-01-15 | Bristol Myers Squibb Co | COMPUESTOS PARA LA REDUCCION DE PRODUCCION DE b-AMILOIDE |
| EP2718287A1 (en) | 2011-06-07 | 2014-04-16 | F.Hoffmann-La Roche Ag | [1,3]oxazines |
| AU2012266544A1 (en) | 2011-06-07 | 2013-11-21 | F. Hoffmann-La Roche Ag | Halogen-alkyl-1,3 oxazines as BACE1 and/or BACE2 inhibitors |
| US8927535B2 (en) * | 2011-07-06 | 2015-01-06 | Hoffman-La Roche Inc. | Cyclopropyl-fused-1,3-thiazepines as BACE1 and/or BACE2 inhibitors |
| RU2014111055A (ru) | 2011-08-22 | 2015-09-27 | Мерк Шарп И Доум Корп. | 2-спирозамещенные иминотиазины и их моно- и диоксиды в качестве ингибиторов bace, композиции и их применение |
| UY34278A (es) | 2011-08-25 | 2013-04-05 | Novartis Ag | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades |
| WO2013030713A1 (en) | 2011-08-31 | 2013-03-07 | Pfizer Inc. | Hexahydropyrano [3,4-d][1,3] thiazin-2-amine compounds |
| US20130073953A1 (en) | 2011-09-21 | 2013-03-21 | Timothy Onyenobi | News headline screenshot viewing system |
| US9284284B2 (en) | 2011-10-13 | 2016-03-15 | Novartis Ag | Oxazine derivatives and their use in the treatment of disease |
| JPWO2013061962A1 (ja) | 2011-10-24 | 2015-04-02 | 武田薬品工業株式会社 | 二環性化合物 |
| KR101669349B1 (ko) | 2012-01-26 | 2016-10-25 | 에프. 호프만-라 로슈 아게 | 플루오로메틸-5,6-다이하이드로-4h-[1,3]옥사진 |
| US9493485B2 (en) | 2012-03-20 | 2016-11-15 | Imago Pharmaceuticals, Inc. | Spirocyclic dihydro-thiazine and dihydro-oxazine BACE inhibitors, and compositions and uses thereof |
| WO2013164730A1 (en) | 2012-05-04 | 2013-11-07 | Pfizer Inc. | Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin- 2 -amine compounds as inhibitors of app, bace1 and bace 2. |
| WO2013182638A1 (en) | 2012-06-08 | 2013-12-12 | H. Lundbeck A/S | 2 -aminothiazinylheteroaryls as bace1 inhibitors for the treatment alzheimer's disease |
| JP6251257B2 (ja) | 2012-06-26 | 2017-12-20 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｂａｃｅ１阻害薬としてのジフルオロ−ヘキサヒドロ−シクロペンタオキサジニル類及びジフルオロ−ヘキサヒドロ−ベンゾオキサジニル類 |
| GB201212871D0 (en) | 2012-07-20 | 2012-09-05 | Eisai Ltd | Novel compounds |
| JP2015529239A (ja) | 2012-09-20 | 2015-10-05 | ファイザー・インク | アルキル置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物 |
| WO2014059185A1 (en) | 2012-10-12 | 2014-04-17 | Amgen Inc. | Amino - dihydrothiazine and amino - dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use |
| WO2014062553A1 (en) | 2012-10-17 | 2014-04-24 | Merck Sharp & Dohme Corp. | Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| EP2908825B1 (en) | 2012-10-17 | 2018-04-18 | Merck Sharp & Dohme Corp. | Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| JP2016501827A (ja) | 2012-10-24 | 2016-01-21 | 塩野義製薬株式会社 | Ｂａｃｅ１阻害作用を有するジヒドロオキサジンまたはオキサゼピン誘導体 |
| CA2886507C (en) | 2012-10-26 | 2016-09-20 | Eli Lilly And Company | Bace inhibitors |
| US9447085B2 (en) | 2012-12-14 | 2016-09-20 | Merck Sharp & Dohme Corp. | Iminothiadiazine dioxides containing a thioamide, amidine, or amide oxime group as BACE inhibitors, compositions, and their use |
| EP2935256B1 (en) | 2012-12-19 | 2018-01-24 | Bristol-Myers Squibb Company | 4,6-diarylaminothiazines as bace1 inhibitors and their use for the reduction of beta-amyloid production |
| CA2893333C (en) | 2012-12-19 | 2017-10-24 | Pfizer Inc. | Carbocyclic-and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| CN104870000A (zh) | 2012-12-20 | 2015-08-26 | 默沙东公司 | 作为bace抑制剂的c5,c6氧杂环稠合的亚胺基噻嗪二氧化物化合物,组合物及其用途 |
| US9580396B2 (en) | 2012-12-21 | 2017-02-28 | Merck Sharp & Dohme Corp. | C6-spiro iminothiadiazine dioxides as BACE inhibitors, compositions, and their use |
| CN104968660A (zh) | 2013-01-22 | 2015-10-07 | 霍夫曼-拉罗奇有限公司 | 作为bace1抑制剂的氟-[1,3]噁嗪类化合物 |
| AU2014223334C1 (en) | 2013-03-01 | 2018-10-18 | Amgen Inc. | Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| EP2964644B1 (en) * | 2013-03-08 | 2018-12-26 | Amgen, Inc. | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| CN105190923B (zh) | 2013-03-15 | 2018-11-27 | 纳米复合材料公司 | 用作应变仪的复合材料 |
| MY174747A (en) | 2013-04-11 | 2020-05-13 | Hoffmann La Roche | Bace1 inhibitors |
| HK1213562A1 (zh) | 2013-04-26 | 2016-07-08 | 豪夫迈‧罗氏有限公司 | Bace抑制剂的合成 |
| TW201623295A (zh) | 2014-04-11 | 2016-07-01 | 塩野義製藥股份有限公司 | 具有ｂａｃｅ１抑制活性之二氫噻及二氫衍生物 |
| MX381482B (es) | 2014-08-08 | 2025-03-12 | Amgen Inc | Compuestos de tiazin-2-amina fusionados con ciclopropilo como inhibidores de beta-secretasa y metodos de uso. |
-
2014
- 2014-03-06 EP EP14717004.7A patent/EP2964644B1/en active Active
- 2014-03-06 WO PCT/US2014/021412 patent/WO2014138484A1/en not_active Ceased
- 2014-03-06 SG SG11201507196WA patent/SG11201507196WA/en unknown
- 2014-03-06 EA EA201591614A patent/EA201591614A1/ru unknown
- 2014-03-06 AU AU2014225604A patent/AU2014225604B2/en active Active
- 2014-03-06 CA CA2903215A patent/CA2903215C/en active Active
- 2014-03-06 US US14/199,844 patent/US9085576B2/en active Active
- 2014-03-06 PE PE2015001879A patent/PE20151794A1/es not_active Application Discontinuation
- 2014-03-06 AP AP2015008716A patent/AP2015008716A0/xx unknown
- 2014-03-06 MX MX2015011618A patent/MX374512B/es active IP Right Grant
- 2014-03-06 BR BR112015021336A patent/BR112015021336A2/pt not_active IP Right Cessation
- 2014-03-06 JP JP2015561682A patent/JP6374889B2/ja active Active
- 2014-03-06 HK HK16105452.2A patent/HK1217486A1/zh unknown
- 2014-03-06 CN CN201480013095.9A patent/CN105164121A/zh active Pending
- 2014-03-06 KR KR1020157026887A patent/KR20150124985A/ko not_active Withdrawn
- 2014-03-07 TW TW103108045A patent/TW201446760A/zh unknown
- 2014-03-10 UY UY0001035377A patent/UY35377A/es not_active Application Discontinuation
-
2015
- 2015-04-21 US US14/691,715 patent/US20150252011A1/en not_active Abandoned
- 2015-08-25 IL IL240829A patent/IL240829A0/en unknown
- 2015-08-31 TN TN2015000382A patent/TN2015000382A1/en unknown
- 2015-09-08 PH PH12015502001A patent/PH12015502001A1/en unknown
- 2015-09-08 CL CL2015002516A patent/CL2015002516A1/es unknown
- 2015-10-05 CR CR20150519A patent/CR20150519A/es unknown
- 2015-11-04 US US14/932,787 patent/US9611261B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2511268A1 (en) * | 2009-12-11 | 2012-10-17 | Shionogi & Co., Ltd. | Oxazine derivative |
Also Published As
| Publication number | Publication date |
|---|---|
| US9085576B2 (en) | 2015-07-21 |
| SG11201507196WA (en) | 2015-10-29 |
| UY35377A (es) | 2014-09-30 |
| CL2015002516A1 (es) | 2016-03-28 |
| KR20150124985A (ko) | 2015-11-06 |
| EA201591614A1 (ru) | 2015-12-30 |
| US20160280695A1 (en) | 2016-09-29 |
| JP6374889B2 (ja) | 2018-08-15 |
| EP2964644A1 (en) | 2016-01-13 |
| PE20151794A1 (es) | 2015-12-03 |
| BR112015021336A2 (pt) | 2017-07-18 |
| TN2015000382A1 (en) | 2017-01-03 |
| US20150252011A1 (en) | 2015-09-10 |
| MX2015011618A (es) | 2015-12-17 |
| CA2903215C (en) | 2021-07-20 |
| IL240829A0 (en) | 2015-10-29 |
| HK1217486A1 (zh) | 2017-01-13 |
| AU2014225604A1 (en) | 2015-09-10 |
| US20140275058A1 (en) | 2014-09-18 |
| EP2964644B1 (en) | 2018-12-26 |
| PH12015502001A1 (en) | 2016-01-11 |
| CN105164121A (zh) | 2015-12-16 |
| AP2015008716A0 (en) | 2015-09-30 |
| CA2903215A1 (en) | 2014-09-12 |
| JP2016510758A (ja) | 2016-04-11 |
| MX374512B (es) | 2025-03-06 |
| WO2014138484A1 (en) | 2014-09-12 |
| CR20150519A (es) | 2016-01-11 |
| TW201446760A (zh) | 2014-12-16 |
| US9611261B2 (en) | 2017-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2964644B1 (en) | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use | |
| US9296734B2 (en) | Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use | |
| US9556135B2 (en) | Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use | |
| US10246429B2 (en) | Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use | |
| AU2015301028B2 (en) | Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use | |
| US20110251186A1 (en) | Amino-Oxazines and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use | |
| US9309263B2 (en) | Fused multi-cyclic sulfone compounds as inhibitors of beta-secretase and methods of use thereof | |
| US9096615B2 (en) | Bridged bicyclic amino thiazine dioxide compounds as inhibitors of beta-secretase and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |